Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease Feb 14, 2017
DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) Feb 14, 2017
DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) Jan 26, 2017
RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections Jan 12, 2017
RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection Jan 11, 2017
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083 Jan 10, 2017
RedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management Jan 10, 2017
RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference Jan 7, 2017
Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA Jan 6, 2017
Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders Dec 17, 2016
DelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083 Dec 15, 2016
Resverlogix Announces Filing of Quarterly Financial Statements and Management’s Discussion & Analysis Dec 14, 2016
Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208) Dec 6, 2016
DelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual Meeting Nov 22, 2016
Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies Nov 18, 2016